Seattle, WA (Press Release) – AVM Biotech­nol­ogy has been awarded a National Cancer In­sti­tute Small Business Innovation Re­search (SBIR) Grant from the National In­sti­tutes of Health (NIH) to study the use of their lead mol­e­cule AVM0703 as a pre­con­di­tion­ing agent to allow safe and efficient de­livery of thera­peutic im­mune cells for cancer treat­ment. This novel solu­tion could offer clin­i­cal ad­van­tages to any cell-based immuno­therapy, im­prov­ing access to poten­tially life-saving ther­a­pies by all cancer patients, in­clud­ing those too frail to re­ceive chemo­ther­apy.

Cellular immuno­therapy has the poten­tial to be­come a crucial solu­tion for cancer. …